Chimerix
Yahoo Finance • 10 months ago
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified... Full story
Yahoo Finance • 11 months ago
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced... Full story
Yahoo Finance • 11 months ago
Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript November 2, 2023 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.22. Operator: Good morning, ladies and gentlemen, and welcom... Full story
Yahoo Finance • 11 months ago
Q3 2023 Chimerix Inc Earnings Call
Participants Michelle LaSpaluto; IR & Vice President Strategic Planning; Chimerix, Inc. Mike Andriole; President & CEO; Chimerix, Inc. Joshua Allen; Chief Technology Officer; Chimerix, Inc. Allen Melemed; Chief Medical Officer; Chimeri... Full story
Yahoo Finance • 11 months ago
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024... Full story
Yahoo Finance • 11 months ago
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced... Full story
Yahoo Finance • last year
Chimerix to Participate in Upcoming Investor Conferences
DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced... Full story
Yahoo Finance • last year
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways DUR... Full story
Yahoo Finance • last year
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mis... Full story
Yahoo Finance • last year
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 – – Completion of ONC206 Dose Escalation Expected by First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM,... Full story
Yahoo Finance • last year
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced... Full story
Yahoo Finance • last year
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients Multiple Preclinical Datasets Support Potential of Imipridone Platform DURHAM, N.C., April 18, 2023 (GLOBE NEWSWIRE) -... Full story
Yahoo Finance • 2 years ago
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Str... Full story
Yahoo Finance • 2 years ago
Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced... Full story
Yahoo Finance • 2 years ago
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced... Full story
Yahoo Finance • 2 years ago
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis – – Two external analyses presented at SNO co... Full story
Yahoo Finance • 2 years ago
Chimerix Responds to Rubric Capital Management
DURHAM, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, issued the follo... Full story
Yahoo Finance • 2 years ago
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November – – Meeting with U.S. Food and Drug Administration (FDA) Set for Fourth Quarter – – Strong Financial Position with ~$285 Million in Cash at September 30 – – Conferenc... Full story
Yahoo Finance • 2 years ago
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that... Full story
Yahoo Finance • 2 years ago
Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announ... Full story
